All In Biotech

Drug Trial Radar · NCT05092269

A Long-term Extension Study of Ustekinumab in Pediatric Participants

A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

159

Actual

Start

Oct 18, 2021

Primary completion

Sep 29, 2027

Study completion Mar 15, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab

Conditions

  • Crohn Disease
  • Colitis, Ulcerative
  • Arthritis, Psoriatic

Interventions

  • UstekinumabDrug

    Ustekinumab will be administered as a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to 6 years and 4 months
  2. Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to 6 years and 4 months
  3. Number of Participants with AEs Leading to Discontinuation of Study InterventionTime frame: Up to 6 years and 4 months
  4. Number of Participants with AEs of InterestTime frame: Up to 6 years and 4 months
  5. Number of Participants with Abnormalities in Clinical Laboratory ParametersTime frame: Up to 6 years and 4 months
  6. Number of Participants with Injection-site ReactionsTime frame: Up to 6 years and 4 months
  7. Number of Participants With AEs of Worsening of the DiseaseTime frame: Up to 6 years and 4 months
  8. Number of Participants With Concomitant Therapy due to Loss of ResponseTime frame: Up to 6 years and 4 months

Locations

48 sites in 13 countries. Site status is shown where the registry gives one.

  • Children's Center For Digestive Healthcare, Llc

    Atlanta, Georgia

  • Mount Sinai

    New York, New York

  • Levine Childrens at Atrium Health

    Charlotte, North Carolina

  • Pediatric Specialists Of Virginia

    Fairfax, Virginia

  • STAT Research S A

    Buenos Aires, Argentina

  • Hospital de Ninos de Cordoba

    Córdoba, Argentina

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina

  • Huderf

    Brussels, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Brussel

    Jette, Belgium

  • Uz Gasthuisberg

    Leuven, Belgium

  • Hôpital Necker

    Paris, France

  • Universitaetsklinikum der RWTH Aachen

    Aachen, Germany

  • Charite Universitatsmedizin Berlin Campus Virchow Klinikum

    Berlin, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary

  • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz

    Miskolc, Hungary

  • Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz

    Nyíregyháza, Hungary

  • Szegedi Tudomanyegyetem

    Szeged, Hungary

  • Yitzhak Shamir Medical Center

    Beer Yaakov, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano

    Milan, Italy

  • Juntendo University Hospital

    Bunkyō City, Japan

  • Gunma University Hospital

    Gunma, Japan

  • Kindai University Nara Hospital

    Ikoma, Japan

  • Kurume University Hospital

    Kurume, Japan

  • Saitama Childrens Medical Center

    Saitama Shi, Japan

  • Miyagi Childrens Hospital

    Sendai, Japan

  • National Center for Child Health and Development

    Setagaya Ku, Japan

  • Mie University Hospital

    Tsu, Japan

  • Uniwersytecki Szpital Dzieciecy w Krakowie

    Krakow, Poland

  • Korczowski Bartosz Gabinet Lekarski

    Rzeszów, Poland

  • Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu Sp z o o

    Sosnowiec, Poland

  • GASTROMED Sp. z o.o.

    Torun, Poland

  • Instytut Pomnik Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Medical Network 1

    Warsaw, Poland

  • Medical Network

    Warsaw, Poland

  • Hosp. Univ. I Politecni La Fe

    Valencia, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.